22nd Mar 2021 14:32
Evgen Pharma PLC - clinical stage drug development company focused on cancer treatment - Says Helen Kuhlman will be joining the company as chief business officer, effective from the start of April. Kuhlman has over 20 years' experience in government funding and equity investment together with scientific and business roles in public and private research & development-based biotechnology companies. She joins Evgen from the Development Bank of Wales where she was responsible for equity investment in technology companies and for managing investments in the bank's portfolio companies.
Current stock price: 7.95 pence, down 1.2% on Monday
Year-to-date change: down 22%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
EVG.L